Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
GNI Group ( (JP:2160) ) has shared an update.
GNI Group Ltd. reported its consolidated financial results for the third quarter of fiscal year 2025, showing a revenue increase of 12.6% year-on-year to 19,357 million yen. However, the company faced operating and pre-tax losses, with a notable decline in profit attributable to owners of the parent. Despite the revenue growth, the financial results indicate challenges in profitability, which may impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2291.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is listed on the Tokyo Stock Exchange under stock code 2160.
Average Trading Volume: 1,100,268
Technical Sentiment Signal: Hold
Current Market Cap: Yen141.3B
For an in-depth examination of 2160 stock, go to TipRanks’ Overview page.